- |||||||||| vebicorvir (ABI-H0731) / Assembly Biosci
Trial completion date, Trial termination, Trial primary completion date: A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - Apr 4, 2023 P2a, N=65, Terminated, Available data indicate that adding VBR to AB-729+NrtI does not result in significantly greater on- or post-treatment improvements in markers of active HBV infection vs AB-729+NrtI. Trial completion date: Jan 2024 --> Mar 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Feb 2023; Sponsor decision
- |||||||||| vebicorvir (ABI-H0731) / Assembly Biosci
Enrollment closed, Trial completion date, Trial primary completion date: A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection (clinicaltrials.gov) - Mar 31, 2022 P2a, N=60, Active, not recruiting, These subjects (and any others from this study who may discontinue NA in the future) will be followed for at least 48 weeks post-NA discontinuation to assess for sustained viral response and evidence of functional cure. Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
|